Compare Medpace Holdings Inc (MEDP) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs UnitedHealth Group Inc — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while UnitedHealth Group Inc trades at $421.62 (market cap $382.83B). The key difference: UnitedHealth Group Inc is far larger — about 25.4× Medpace Holdings Inc's market cap, and UnitedHealth Group Inc pays a 2.2% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | UNH | |
|---|---|---|
Market Cap | $15.08B | $382.83B |
Sector | Technology | Health |
52-Week High | $620.59 | $431.68 |
52-Week Low | $308.88 | $237.77 |
Enterprise Value | $14.55B | $429.52B |
Dividend Yield | — | 2.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
UnitedHealth Group (UNH) trades at $421.55, down 1.07% today, with strong bullish technical signals and consistent earnings beats. Revenue reached $447.57B in 2025, though net margins compressed to 2.68%. The company maintains robust cash flow from operations at $19.70B and announced a $2.32 dividend for H1 2026. Recent news highlights strategic moves to reduce pediatric prior authorizations, aiming to improve care access and operational efficiency.
Outlook remains positive with analyst consensus targeting $466.41, representing ~11% upside. Key opportunities include aging demographics and tech-driven healthcare adoption. Risks involve regulatory scrutiny, as seen in Massachusetts' Medicaid lawsuit, and margin pressure from rising costs. Institutional sentiment is strongly bullish with 82.7% buy ratings, supporting long-term growth prospects amid sector tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
